A key piece of OSE Immunotherapeutics’ business model
For OSE Immunotherapeutics, partnerships and out-licensing deals with global pharmaceutical companies represent ways to rapidly advance the clinical development of its product candidates. Selective partnerships represent a key piece of OSE’s business model that can contribute significantly to the cash flow needed to continue discovering and developing new targets and therapeutic candidates.
OSE Immunotherapeutics is actively pursuing a partnership strategy with potential pharmaceutical partners.
Existing partnerships signed with premier international pharmaceutical companies for the clinical development of the Company’s most advanced and innovative programs include the following:
Each of these agreements includes an initial upfront payment as well as milestone payments and royalties on potential future sales.
Together, existing partnerships represent a potential of up to €1.4 billion of revenue for OSE Immunotherapeutics and additional royalties on future sales, demonstrating our expertise discovering valuable new targets and therapies and validating the high potential of our drug candidates.